Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer.
Setrusumab (100 mg/kg; i.v. once a week for 4 weeks) inhibits breast cancer-induced bone metastases and muscle weakness in mice[1].
References:
[1]. Hesse E, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019 Apr 9;5(9):e125543.